Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Authors' Reply to Lechat et al.: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Aug 27. doi: 10.1007/s40262-019-00815-8. [Epub ahead of print] No abstract available.

PMID:
31452151
2.

Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Aug 21. doi: 10.1007/s40262-019-00812-x. [Epub ahead of print]

PMID:
31432471
3.

Author's Reply to Trechot: "Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Jul;58(7):979-980. doi: 10.1007/s40262-019-00787-9. No abstract available.

PMID:
31187472
4.

Authors' Reply to Castello-Bridoux et al.: "Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Jul;58(7):973-975. doi: 10.1007/s40262-019-00786-w. No abstract available.

5.

Authors' Reply to Nicolas: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Jul;58(7):961-963. doi: 10.1007/s40262-019-00781-1. No abstract available.

6.

Authors' Reply to Coste et al.: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Jul;58(7):967-968. doi: 10.1007/s40262-019-00780-2. No abstract available.

7.

Comparison of in vitro static and dynamic assays to evaluate the efficacy of an antimicrobial drug combination against Staphylococcus aureus.

Broussou DC, Toutain PL, Woehrlé F, El Garch F, Bousquet-Melou A, Ferran AA.

PLoS One. 2019 Jan 23;14(1):e0211214. doi: 10.1371/journal.pone.0211214. eCollection 2019.

8.

Differential Activity of the Combination of Vancomycin and Amikacin on Planktonic vs. Biofilm-Growing Staphylococcus aureus Bacteria in a Hollow Fiber Infection Model.

Broussou DC, Lacroix MZ, Toutain PL, Woehrlé F, El Garch F, Bousquet-Melou A, Ferran AA.

Front Microbiol. 2018 Mar 27;9:572. doi: 10.3389/fmicb.2018.00572. eCollection 2018.

9.

En Route towards European Clinical Breakpoints for Veterinary Antimicrobial Susceptibility Testing: A Position Paper Explaining the VetCAST Approach.

Toutain PL, Bousquet-Mélou A, Damborg P, Ferran AA, Mevius D, Pelligand L, Veldman KT, Lees P.

Front Microbiol. 2017 Dec 15;8:2344. doi: 10.3389/fmicb.2017.02344. eCollection 2017. Review.

10.

Infection-stage adjusted dose of beta-lactams for parsimonious and efficient antibiotic treatments: A Pasteurella multocida experimental pneumonia in mice.

Vasseur MV, Lacroix MZ, Toutain PL, Bousquet-Melou A, Ferran AA.

PLoS One. 2017 Aug 4;12(8):e0182863. doi: 10.1371/journal.pone.0182863. eCollection 2017.

11.

In vitro Degradation of Antimicrobials during Use of Broth Microdilution Method Can Increase the Measured Minimal Inhibitory and Minimal Bactericidal Concentrations.

Lallemand EA, Lacroix MZ, Toutain PL, Boullier S, Ferran AA, Bousquet-Melou A.

Front Microbiol. 2016 Dec 21;7:2051. doi: 10.3389/fmicb.2016.02051. eCollection 2016.

12.

Veterinary Medicine Needs New Green Antimicrobial Drugs.

Toutain PL, Ferran AA, Bousquet-Melou A, Pelligand L, Lees P.

Front Microbiol. 2016 Aug 3;7:1196. doi: 10.3389/fmicb.2016.01196. eCollection 2016. Review.

13.

Comparison of the In vitro Activity of Five Antimicrobial Drugs against Staphylococcus pseudintermedius and Staphylococcus aureus Biofilms.

Ferran AA, Liu J, Toutain PL, Bousquet-Mélou A.

Front Microbiol. 2016 Aug 2;7:1187. doi: 10.3389/fmicb.2016.01187. eCollection 2016.

14.

Impact of Timing and Dosage of a Fluoroquinolone Treatment on the Microbiological, Pathological, and Clinical Outcomes of Calves Challenged with Mannheimia haemolytica.

Lhermie G, Ferran AA, Assié S, Cassard H, El Garch F, Schneider M, Woerhlé F, Pacalin D, Delverdier M, Bousquet-Mélou A, Meyer G.

Front Microbiol. 2016 Mar 2;7:237. doi: 10.3389/fmicb.2016.00237. eCollection 2016.

15.

Bacterial Species-Specific Activity of a Fluoroquinolone against Two Closely Related Pasteurellaceae with Similar MICs: Differential In Vitro Inoculum Effects and In Vivo Efficacies.

Lhermie G, El Garch F, Toutain PL, Ferran AA, Bousquet-Mélou A.

PLoS One. 2015 Oct 27;10(10):e0141441. doi: 10.1371/journal.pone.0141441. eCollection 2015.

16.

Comparison of the reduction in the antibacterial potency of a fluoroquinolone conferred by a single mutation in the quinolone resistance-determining region or by the inoculum size effect.

Ferran AA, Toutain PL, Bousquet-Melou A.

Int J Antimicrob Agents. 2014 Nov;44(5):472-4. doi: 10.1016/j.ijantimicag.2014.07.007. Epub 2014 Aug 23. No abstract available.

PMID:
25442360
17.

Use of Monte Carlo simulation to determine pharmacodynamic cutoffs of amoxicillin to establish a breakpoint for antimicrobial susceptibility testing in pigs.

Rey JF, Laffont CM, Croubels S, De Backer P, Zemirline C, Bousquet E, Guyonnet J, Ferran AA, Bousquet-Melou A, Toutain PL.

Am J Vet Res. 2014 Feb;75(2):124-31. doi: 10.2460/ajvr.75.2.124.

PMID:
24471748
18.

Low or high doses of cefquinome targeting low or high bacterial inocula cure Klebsiella pneumoniae lung infections but differentially impact the levels of antibiotic resistance in fecal flora.

Vasseur MV, Laurentie M, Rolland JG, Perrin-Guyomard A, Henri J, Ferran AA, Toutain PL, Bousquet-Mélou A.

Antimicrob Agents Chemother. 2014;58(3):1744-8. doi: 10.1128/AAC.02135-13. Epub 2014 Jan 6.

19.

Pharmacokinetic/pharmacodynamic assessment of the effects of parenteral administration of a fluoroquinolone on the intestinal microbiota: comparison of bactericidal activity at the gut versus the systemic level in a pig model.

Ferran AA, Bibbal D, Pellet T, Laurentie M, Gicquel-Bruneau M, Sanders P, Schneider M, Toutain PL, Bousquet-Melou A.

Int J Antimicrob Agents. 2013 Nov;42(5):429-35. doi: 10.1016/j.ijantimicag.2013.07.008. Epub 2013 Aug 19.

PMID:
24021905
20.

Impact of early versus later fluoroquinolone treatment on the clinical; microbiological and resistance outcomes in a mouse-lung model of Pasteurella multocida infection.

Ferran AA, Toutain PL, Bousquet-Mélou A.

Vet Microbiol. 2011 Mar 24;148(2-4):292-7. doi: 10.1016/j.vetmic.2010.09.005. Epub 2010 Sep 15.

21.

Influence of inoculum size and marbofloxacin plasma exposure on the amplification of resistant subpopulations of Klebsiella pneumoniae in a rat lung infection model.

Kesteman AS, Ferran AA, Perrin-Guyomard A, Laurentie M, Sanders P, Toutain PL, Bousquet-Mélou A.

Antimicrob Agents Chemother. 2009 Nov;53(11):4740-8. doi: 10.1128/AAC.00608-09. Epub 2009 Sep 8.

22.

Pharmacokinetic/pharmacodynamic analysis of the influence of inoculum size on the selection of resistance in Escherichia coli by a quinolone in a mouse thigh bacterial infection model.

Ferran AA, Kesteman AS, Toutain PL, Bousquet-Mélou A.

Antimicrob Agents Chemother. 2009 Aug;53(8):3384-90. doi: 10.1128/AAC.01347-08. Epub 2009 Jun 1.

Supplemental Content

Loading ...
Support Center